A Single-center, Randomized, Double-blind, Parallel, Placebo-controlled, Multiple Consecutive Dose Study to Assess the Tolerability, Pharmacokinetics and Pharmacodynamics of HEC74647 in Subjects With Chronic Hepatitis C Virus Infection
Latest Information Update: 22 Feb 2021
Price :
$35 *
At a glance
- Drugs HEC 74647PA (Primary)
- Indications Hepatitis C
- Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
- Sponsors Sunshine Lake Pharma
- 17 Mar 2020 Status changed from not yet recruiting to completed.
- 19 Dec 2019 New trial record